Mainz Biomed Develops Breakthrough Colorectal Cancer Test
Mainz Biomed's breakthrough colorectal cancer test offers hope for improved early detection and survival rates, potentially impacting the multi-billion dollar U.S. market for colorectal screening and expanding into other gastrointestinal cancers.
The development of a more effective and non-invasive colorectal cancer test by Mainz Biomed could significantly improve early detection and survival rates for this deadly disease. It also has the potential to impact the multi-billion dollar U.S. market for colorectal screening, as well as expand into other gastrointestinal cancers.